PRME: Prime Editing advances versatile gene therapies with strong clinical and financial momentum
Prime Editing offers broad, precise, and safe genome editing, with clinical progress in CGD, Wilson disease, and Alpha-1 programs. Regulatory flexibility and platform synergies support rapid expansion, while a strong cash position extends runway into 2027.Based on Prime Medicine, Inc. [PRME] H.C. W…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.